Carlos Cruz
@_crcruz
@opentargets maintainer. Lead frontend developer @emblebi 🇨🇷
Excited to share our "Associations on the Fly" paper in Oxford Bioinformatics!🧬 In @OpenTargets we built this tool to visualise multi-level data on a single screen, helping researchers navigate complex evidence without switching context. Check it out: academic.oup.com/bioinformatics…
With the gget opentargets module, you can now interact directly with the Open Targets database from a Python or command line environment Developed by @NeuroLuebbert, gget is a free, open-source tool enabling efficient querying of large genomic databases blog.opentargets.org/case-study-gge…
Happy birthday to our colleagues in @OpenTargets 🥳 Enjoy a well deserved celebration after 10 years of pushing the boundaries of drug discovery. Here’s to the next 10 years!
Happy 10th birthday Open Targets! 🎉 Thank you to everyone who has worked to make Open Targets what it is today. Here's to the next 10! 🥂 #OpenTargetsAt10
Para que los costarricenses lo leamos todos los días. Hagámonos cargo.
Es atroz. ¡¡Así es como le van destruyendo la calidad de vida a la gente!! Este desastre de política pública pro-caos vial produce enfermedad crónica, depresión y agresividad. No puede ser que la ciudadanía siga tolerando este desastre.
Thanks to the @OpenTargets tech team for supporting the organic development of features and constant refactoring in AotF Seeing the tool's progress over every release demonstrates our dedication and commitment to our users and our confidence in our team's creativity 🤘🚀
🚨 Open Targets Platform 24.09 is out today!
One of my favorite PhD theses (about architectural complexity) literally cites "Some engineers in the study had 10x more output, this drowned out all other measurable effects" as a big challenge in its methodology section
“"10X engineers are a myth, and believing in them is harmful." Quite the contrary. In many teams, a small fraction of the workforce often generates the majority of outcomes. Recognizing and nurturing high-performing individuals isn't just realistic—it's crucial.” My brother from…
Why do so many React developers dislike useReducer()?
Happy to be part of the history of @OpenTargets 👏🎉
Double digits! Open Targets was founded 10 years ago today 🎂 Over the next year, we'll be reflecting on key achievements and looking forward to the next decade and beyond... #OpenTargetsAt10 Congratulations to the whole team at Open Targets, past and present!🥂
Happy #InternationalMotherLanguageDay! Our team celebrated by sharing some of their favourite words and phrases with each other — how many do you know? 🇺🇸🇮🇹🇨🇳🇪🇸🇮🇷🇩🇪🇰🇪🇬🇧🇷🇺🇮🇳🇨🇴🇵🇱🌍
The Open Targets Platform has had some exciting updates ✨ Join our webinar next week to find out how you can use the Platform to explore target-disease associations and more with our new Associations on the Fly and Target Prioritisation views See you there!
Join our #webinar next week to learn how you can explore drug target-disease associations @OpenTargets. Registration is free but essential: ebi.ac.uk/training/event… #DrugDiscovery #drugtarget #FunctionalGenomics #DataScience
Thrilled to share my first PhD paper in @NatureComms! "The D-Mercator method for the multidimensional hyperbolic embedding of real networks" (nature.com/articles/s4146…). Big thanks to my amazing co-authors @all_are, Marian Boguña & M. Ángeles Serrano!
How do you maintain a high quality engineering culture without relying on a few caring individuals burning out?
Great to see a lot of UI additions and improvements on this release! Associations on the fly tool rocking with new features to empower our users 🎸🤘 Stay tuned for our major refactor next year to add server-side render capabilities!! @nextjs or @remix_run ? 👀
🚀 The Open Targets Platform’s release (❄️ 23.12) is out now! 🚥 It introduces the Target Prioritisation view — a traffic light scoring system to help you to assess target features of interest for drug discovery
🚨 We are hiring at @OpenTargets 🚨 Web developer role with a variety of domain labels (Jr/Mid/Sr). Help us maintain our main UI applications and also integrate new server-side capabilities as new services and SSR DM me with any questions/comments embl.org/jobs/position/…
Genetic support for FDA-approved drugs over the past decade bit.ly/3Q5WIvo This new analysis shows that available genetic evidence supported 63% of the new drugs approved by the FDA from 2013-2022